First- and Second-Line Treatment Options in Lower-Risk MDS

Video

Hematologic oncology experts give an overview of first- and second-line treatment options for lower-risk myelodysplastic syndromes.

Related Videos
Elias Jabbour, MD
Marc J. Braunstein, MD, PhD
Samer A. Srour, MB ChB, MS
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Jorge J. Castillo, MD,
Christina L. Roland, MD, MS, FACS
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Naomi Adjei, MD, MPH, MSEd, gynecologic oncology fellow, The University of Texas MD Anderson Cancer Center
Related Content
He Huang, MD, PhD, of First Affiliated Hospital, Zhejiang University School of Medicine

CD7 CAR T-Cell Therapy Plus Allogeneic HSCT Is Safe, Feasible in CD7+ Hematologic Malignancies

April 24th 2024
Article
Elias Jabbour, MD, professor, medicine, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center

FDA Approval Insights: Ponatinib in Ph+ ALL

April 8th 2024
Podcast
US FDA

FDA Grants Breakthrough Therapy Designation to Ziftomenib in NPM1-Mutant AML

April 22nd 2024
Article
John H. Strickler, MD, associate professor, medicine, member, the Duke Cancer Institute; Michael Leung, PharmD, BCOP, clinical pharmacy specialist, Gastrointestinal (GI) Medical Oncology, The University of Texas MD Anderson Cancer Center; Arvind N. Dasari, MD, MS, associate professor, the Department of GI Medical Oncology, the Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center; Margot O’Neill, PA-C, MHS, physician assistant, oncology, the Duke Cancer Institute

CRC Experts Highlight AE Management and Prevention Strategies for TAS-102/Bevacizumab, Regorafenib, and Fruquintinib

March 25th 2024
Podcast
OncLive On Air

Revisit Every OncLive On Air Episode from March 2024

April 19th 2024
Article
FDA

FDA Requires Boxed Warning for Risk of T-Cell Malignancies With Approved CAR T-Cell Therapies

April 19th 2024
Article